Amzoiu D C, Pisoschi C G, Stoian Bulearcă A M, Rău G
University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Department of Pharmaceutical Chemistry.
University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Department of Biochemistry.
Curr Health Sci J. 2016 Jan-Mar;42(1):29-34. doi: 10.12865/CHSJ.42.01.04. Epub 2016 Mar 29.
The main objective of this study was the comparison of the influence for three non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the oxicam class, namely piroxicam and tenoxicam, as non-selective inhibitors of cyclooxygenase (COX), and meloxicam, a selective COX-2 inhibitor, on glutathione peroxidase (GPx) activity in patients with osteoarthritis of the knee.
MATERIAL/METHODS: Thirty adult subjects clinically and radiographically diagnosed with knee osteoarthritis, who were not previously subjected to any treatment, were enrolled. They were divided in three groups, each with ten subjects. The serum levels of GPx were assessed at baseline and after twenty days of treatment. The first group received piroxicam at a dose of 20 mg orally daily, the second group was treated with tenoxicam at a dose of 20 mg orally daily, and in the third group meloxicam was administrated in a dose of 15 mg orally daily.
After the treatment, it was observed an increase of the GPx activity in all groups. The group treated with meloxicam presented the highest rise in the GPx level (p = 0.052).
The 20 days study concerning the effects of treatment with NSAIDs belonging to the oxicam class in subjects with knee osteoarthritis revealed that piroxicam, tenoxicam and meloxicam determined a slightly increase in the GPx activity, although this rise had no statistical significance.
本研究的主要目的是比较三种属于昔康类的非甾体抗炎药(NSAIDs),即作为环氧化酶(COX)非选择性抑制剂的吡罗昔康和替诺昔康,以及选择性COX-2抑制剂美洛昔康,对膝骨关节炎患者谷胱甘肽过氧化物酶(GPx)活性的影响。
材料/方法:纳入30名临床和影像学诊断为膝骨关节炎且此前未接受过任何治疗的成年受试者。他们被分为三组,每组10名受试者。在基线和治疗20天后评估GPx的血清水平。第一组每天口服20mg吡罗昔康,第二组每天口服20mg替诺昔康,第三组每天口服15mg美洛昔康。
治疗后,观察到所有组的GPx活性均增加。美洛昔康治疗组的GPx水平升高最为明显(p = 0.052)。
关于昔康类NSAIDs对膝骨关节炎患者治疗效果的20天研究表明,吡罗昔康、替诺昔康和美洛昔康使GPx活性略有增加,尽管这种增加无统计学意义。